Serum macrophage migration‐inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer

Abstract

Serum MIF level, which correlates with gastric MIF expression, is a better molecular marker than CEA in diagnosing gastric cancer in patients presenting with dyspepsia. A combination of serum MIF and CEA predicts 5-year survival better than the individual test.